Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

2.79
+0.18006.90%
Post-market: 2.75-0.0400-1.43%19:55 EDT
Volume:1.05M
Turnover:2.90M
Market Cap:134.78M
PE:-1.91
High:2.80
Open:2.61
Low:2.61
Close:2.61
Loading ...

Company Profile

Company Name:
Cassava Sciences Inc
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
30
Office Location:
6801 N. Capital of Texas Highway,Suite 300,Building 1,Austin,Texas,United States
Zip Code:
78731
Fax:
- -
Introduction:
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Directors

Name
Position
Remi Barbier
President, Chief Executive Officer, Chairman of the Board
Nadav Friedmann
Chief Medical Officer and Director
Michael J. O'donnell
Director
Patrick J. Scannon
Director
Robert Z. Gussin
Director
Sanford R. Robertson
Director

Shareholders

Name
Position
Remi Barbier
President, Chief Executive Officer, Chairman of the Board
Eric J. Schoen
Chief Financial Officer
James W. Kupiec
Chief Clinical Development Officer
Nadav Friedmann
Chief Medical Officer and Director